Investor Presentation - First Six Months of 2021
23
Investor presentation
First six months of 2021
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Novo NordiskⓇ
Diabetes care
DKK
billion
700
600
500
400
300
200
CAGR¹ value: 9.6%
100
0
May
2016
Market value
Obesity care
DKK
billion
#1
50%
12
Haemophilia
DKK
billion
#1
80%
100
#3
50%
10
40%
80
60%
40%
8
30%
60
30%
6
40%
20%
40
20%
4
20%
10%
20
2
CAGR² value: 3.2%
CAGR³ value: 3.0%
10%
0%
0
0%
0
0%
May
2021
May
2019
Market value
May
2021
FY
FY
2016
NN value market share (RHS)
Global market position
NN value market share (RHS)
Global market position
Market value
NN value market share (RHS)
Global market position
2020
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 5-year period; Note: Annual sales figures for haemophilia A, B and bypassing agents segment. Recombinant and plasma derived products
Source: Company reports for haemophilia market, IQVIA MAT, May 2021; Note: Diabetes and Obesity care market values are based on list prices in the US.
NN: Novo NordiskView entire presentation